Therapeutic amoxicillin levels achieved with oral administration in term neonates

Christele Gras-Le Guen1, Cecile Boscher, Nathalie Godon

  • 1Pediatric and Neonatal Critical Care Division, Department of Perinatology, Hôpital Mère Enfant, Centre Hospitalier Universitaire, 38 Bd J Monnet, 44099 Nantes, Cedex, France. christele.grasleguen@chu-nantes.fr

Insights

Switching neonatal group B Streptococcus infection treatment to oral amoxicillin after 48 hours of IV therapy is effective. This approach maintains therapeutic serum amoxicillin concentrations in full-term newborns, potentially reducing invasiveness and hospital stay.

Area of Science:

  • Neonatal Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Neonatal group B Streptococcus (GBS) infection is typically treated with 10 days of intravenous amoxicillin.
  • Effective serum concentrations are crucial for successful treatment outcomes.

Purpose of the Study:

  • To investigate if oral amoxicillin can achieve effective serum concentrations after initial intravenous therapy in full-term neonates with GBS infection.
  • To evaluate the safety and efficacy of switching to oral amoxicillin early in the treatment course.

Main Methods:

  • A study of 222 full-term neonates with early-onset GBS disease who received 48 hours of intravenous amoxicillin.
  • Asymptomatic neonates were switched to oral amoxicillin (300 or 200 mg/kg/day).
  • Serum amoxicillin concentrations were measured 48 hours after switching to oral therapy.

Main Results:

  • All neonates achieved serum amoxicillin concentrations above the effective threshold of 5 mg/l on oral therapy.
  • Median concentrations were 31.15 mg/l (300 mg/kg/day) and 25.80 mg/l (200 mg/kg/day).
  • Gastrointestinal tolerance was good, with no readmissions within 3 months.

Conclusions:

  • Early switch to oral amoxicillin in asymptomatic neonates with GBS disease maintains therapeutic serum concentrations.
  • This strategy offers potential for less invasive treatment and shorter hospital stays.
  • The risk of treatment failure due to low concentrations was minimal (p < 0.001).
Abstract

Related Concept Videos

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...